Rate Video

ASCO 2019 | Patient impact: development of drugs to treat METex14 alterations

Paul Paik • 3 Jun 2019

Paul Paik, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the development of drugs to treat METex14 alterations may impact lung cancer patients. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

VISION trial: subset efficacy analyses of tepotinib for NSCLC

Paul Paik • 26 Jan 2021

Future treatment options for squamous cell lung cancer

Paul Paik • 3 Jun 2019

Squamous cell lung cancer: gene targets

Paul Paik • 3 Jun 2019

Tepotinib: advanced non-small cell lung cancer

Related Videos

BrainStorm: improving prediction, diagnosis and management of brain metastases

Ahmad Awada • 6 May 2021

Impact of COVID-19 on lung cancer diagnosis and outcomes in the UK

David Baldwin • 29 Apr 2021

Cellular therapy in solid tumors

Andrew Furness • 27 Apr 2021

Cellular therapy in NSCLC

Andrew Furness • 27 Apr 2021